Nihon Trim (6788) · InitiativeAdvanced
Expansion of the Regenerative Medicine Business through an Investment in Cuorips Inc.
First written in FY2021-Q3. 1 of 2 entries say "Advanced", first in FY2024-Q2. Latest entry: FY2024-Q2.
2entries
3years
0from disclosures
How it moved
Same theme, other companies
Creating New Businesses through Investments in Testing and Diagnostic Device Companies and Regenerative Medicine CompaniesA theme 7 companies write about · 0 as a headwind · 10 as a tailwind
1 other company's latest entry also says "Advanced".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
- FY2024-Q2AdvancedAnnual report
「Cuorips Inc. (Chuo-ku, Tokyo), in which the company invested in December 2020 and which is advancing the development of iPS cell-derived cardiac muscle cell sheets, listed on the Tokyo Stock Exchange Growth Market in June this year (securities code: 4894).」
Cuorips Inc., an investee, listed on the Tokyo Stock Exchange Growth Market in June this year. - FY2021-Q3First statedAnnual report
「In December 2020, the company invested, together with major pharmaceutical companies and others, in Cuorips Inc. (head office: Chuo-ku, Tokyo), a regenerative medicine venture originating from Osaka University that aims to obtain regulatory approval for an iPS cell-derived cardiac muscle sheet.」
The company made a joint investment in Cuorips Inc., which aims to obtain regulatory approval for an iPS cell-derived cardiac muscle sheet.